Alterity Therapeutics Limited Revenue 2011-2026 | ATHE

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Alterity Therapeutics Limited

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	109 K	201 K	132 K	143 K	177 K	364 K	151 K	2.53 M	163 K

All numbers in AUD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.53 M	109 K	441 K

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	21 M	$ 2.1	-13.79 %	$ 216 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	20 K	$ 4.2	-2.67 %	$ 298 M	USA
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
AVEO Pharmaceuticals AVEO	42.3 M	-	-	$ 521 M	USA
Apellis Pharmaceuticals APLS	1 B	$ 20.61	-1.67 %	$ 2.6 B	USA
Agenus AGEN	156 M	$ 3.33	-	$ 1.19 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Agios Pharmaceuticals AGIO	54 M	$ 28.87	-4.5 %	$ 1.67 B	USA
bluebird bio BLUE	29.5 M	-	-	$ 546 M	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA